Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated indication/usage claim aligns directly with the FDA label: RHAPSIDO is indicated for adult chronic spontaneous urticaria (CSU) in patients symptomatic despite H1 antihistamines, with the label limitation that it is not indicated for other urticaria forms.
Category Scores
Accurate Statements
RHAPSIDO is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment.
Section 1 INDICATIONS AND USAGE: "RHAPSIDO is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment."
RHAPSIDO is limited to CSU and is not indicated for other forms of urticaria.
Section 1 INDICATIONS AND USAGE: "Limitations of Use: RHAPSIDO is not indicated for other forms of urticaria."
Efficacy for CSU in adults symptomatic despite H1 antihistamine treatment was evaluated in two randomized, double-blind, placebo-controlled 52-week trials.
Section 14 CLINICAL STUDIES: "The efficacy of RHAPSIDO for chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment was evaluated in two identical, 52-week..."
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated content pertains only to labeled indication/usage; no dosing, safety, contraindications, warnings, or interaction claims were made to assess.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement